Wall Street Zen cut shares of Vivani Medical (NASDAQ:VANI – Free Report) from a hold rating to a sell rating in a research report report published on Sunday morning,Wall Street Zen reports.
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $3.75.
Check Out Our Latest Stock Analysis on VANI
Vivani Medical Price Performance
Vivani Medical stock opened at $1.01 on Friday. Vivani Medical has a 12 month low of $0.80 and a 12 month high of $1.66. The company has a market cap of $91.10 million, a price-to-earnings ratio of -3.16 and a beta of 2.51. The stock’s 50-day moving average is $1.18 and its 200-day moving average is $1.24.
Vivani Medical (NASDAQ:VANI – Get Free Report) last posted its earnings results on Wednesday, November 11th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01.
About Vivani Medical
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Further Reading
- Five stocks we like better than Vivani Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
